All Stories

  1. Cellular profile of hematopoietic stem cells mobilized by exercise versus G-CSF in healthy related donors
  2. Factor H-related protein 1 in systemic lupus erythematosus
  3. Protecting the blood donor: ferritin-based intervals to improve donor health
  4. Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study
  5. Editorial: Transfusion medicine and blood, volume II
  6. Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation
  7. Développements récents en hématologie, Partie 2
  8. Jüngste Entwicklungen in der Hämatologie, Teil 2
  9. Développements récents en hématologie, Teil 1
  10. Jüngste Entwicklungen in der Hämatologie, Teil 1
  11. Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies
  12. Are we donating iron? Impact of apheresis on ferritin
  13. Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study
  14. Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment
  15. Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light
  16. Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch
  17. Transfusions in Aplastic Anemia Patients Cause HLA Alloimmunization: Comparisons of Current and Past Cohorts Demonstrate Progress
  18. Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation
  19. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery
  20. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions
  21. Identification of Patients with Cobalamin Deficiency Crucially Depends on the Diagnostic Strategy
  22. Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
  23. Long-Term Course of Haemoglobin and Ferritin Values in High-Frequency Donors of Whole Blood and Double Erythrocyte Apheresis
  24. G-CSF Infusion for Stem Cell Mobilization Transiently Increases Serum Cell-Free DNA and Protease Concentrations
  25. Extracorporeal Photopheresis in Graft-versus-Host Disease
  26. Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis
  27. Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days
  28. Transfusion de plaquettes traitées par amotosalen conservées jusqu’à 7 jours
  29. The Remarkable Journey of a Low-Frequency Alloantibody
  30. The value of the post-thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation
  31. Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation
  32. Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016
  33. Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study
  34. International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy
  35. Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary
  36. Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation
  37. In response to the comment by Hechler et al .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
  38. Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload
  39. Red cell apheresis: pros and cons
  40. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
  41. Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization
  42. Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure
  43. Iron deficiency and thrombocytosis
  44. International Forum regarding practices related to donor haemoglobin and iron
  45. Impact of donor ABH‐secretor status in ABO‐mismatched living donor kidney transplantation
  46. MNSs genotyping by MALDI-TOF MS shows high concordance with serology, allows gene copy number testing and reveals new St(a) alleles
  47. Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage
  48. Blood donor to inactive donor transition in the Basel region between 1996 and 2011: a retrospective cohort study
  49. Management of a Pregnant Woman with Anti-Holley Alloantibody
  50. The Intercept Blood System Affects Platelet Function and Survival By Inducing Apoptosis
  51. Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation
  52. Platelet transfusion: basic aspects
  53. Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre
  54. Role of donor and recipient sex in platelet transfusion
  55. Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components
  56. Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells
  57. Switching iron-deficient whole blood donors to plateletpheresis
  58. Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center
  59. Prognostic value of red blood cell parameters and ferritin in predicting deferral due to low hemoglobin in whole blood donors
  60. Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: A cohort study
  61. The value of routine ferritin measurement in blood donors
  62. A pilot Iron Substitution Programme in female blood donors with iron deficiency without anaemia
  63. The Value of Routine Ferritin Measurement In Blood Donors
  64. Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
  65. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies
  66. The Therapy of Primary Adult Systemic CD30-Positive Anaplastic Large Cell Lymphoma: Results of 40 Cases Treated in a Single Center
  67. BCL-2 Immunohistochemical Evaluation in B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Before Treatment with Fludarabine and 2-Chloro-Deoxy-Adenosine
  68. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin’s lymphoma
  69. Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients
  70. Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma Patients
  71. HEPATITIS C VIRUS INFECTION (AND ADDITIONAL NEOPLASMS) AMONG MARGINAL ZONE LYMPHOMAS
  72. Sequential Intensive Treatment with the F-MACHOP Regimen (± Radiotherapy) and Autologous Stem Cell Transplantation for Primary Systemic CD30 (Ki-1)— Positive Anaplastic Large Cell Lymphoma in Adults
  73. Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies [letter; comment]
  74. Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies [letter; comment]
  75. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders
  76. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation